Abstract
Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosac charidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity. Methods: Two groups o 25 obese women were put on a 15 kcal/kg/day low-calorie diet for 12 weeks. One group (the study group) received 150 mg/day acarbose for the first 2 weeks and 300 mg/day acarbose for the remaining 10 weeks. The second group (controls) received no additional treatment. Body weight, BMI, skinfold thickness, serum lipids, OGTT, and insulin and C-peptide responses to OGTT were assessed before and after the study. Results: Body weight, BM and skinfold thickness decreased significantly in both groups. Basal insulin and triglyceride levels in the study group, total and LDL cholesterol and triglyceride levels in the contro group decreased significantly. No difference was found between the two groups when these decrements were compared, but the triglyceride level fell more in the control group Conclusion: Additional acarbose therapy is not more beneficial than low-calorie diet therapy alone.
References
Gray D.S.: Diagnosis and prevalence of obesity. Med. Clin. North Am., 73, 1–13, 1989.
NIH Tecnology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann. Intern. Med. 119, 764, 1993.
Hodge A.M., Zimmet P.Z.: The epidemiology of obesity. Baillieres Clin. Endocrinol. Metab., 8, 577–599, 1994.
Bray G.A., Ryan D.H.: Drugs used in the treatment of obesity. Diabetes Reviews, 5, 83–103, 1997.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 329, 977–986, 1993.
Defronzo R.A., Ferrannini E.: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care, 14, 173–194, 1991.
Moller D.E., Flier J.S.: Insulin resistancemechanisms, syndromes and implications. N. Engl. J. Med., 325, 938–948, 1991.
Clissold S.P., Edwards C.: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 35, 214–243, 1988.
Maggio C.A., Vasselli J.R.: Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421). Physiol. Behav., 46, 557–560, 1989.
Couet C., Ulmer M., Hamdaoui M., Bau H.M., Debry G.: Metabolic effects of acarbose in young healthy men. Eur. J. Clin. Nutr., 43, 187–196, 1989.
William-Olsson T.: Alpha-glucosidase inhibition in obesity. Acta Med. Scand., 706, 1–39, 1985.
William-Olsson T., Krotkiewski M., Sjöström L.: Relaps reducing effects of acarbose after weight reduction in severely obese subjects. J. Obes. Weight Regulation, 4, 20–32, 1985.
Goto Y., Toyoda T., Okiawa S., Moruhama Y., Tamura M., et al.: Long term administration of BAY g 5421 (acarbose) in NIDDM. Yakuri to Chiryo, 17, 387–401, 1989.
Goto Y., Nakagawa S., Goto Y., Ikeda Y., Hosoya N., et al.: Utility of BAY g 5421 (acarbose) on NIDDM, multicentre open study. Kiso to Rinsho, 23, 219–239, 1989.
Sakamoto N., Shibata M., Hotta N., Kakuta H., Tomita A., et al.: Clinical study on BAY g 5421 (acarbose) for non-insulin-dependent diabetes mellitus (NIDDM). Yakuri to Chiryo, 17, 633–649, 1989.
Coli P., Pea E., Lacorte M., Passaglia C., Carrai M.: Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose. Min. Med., 87, 161–170, 1996.
Fried S.K., Maggio C.A., Vasselli J.R.: Effets of Acarbose on Insulin Sensitivity in Adipocytes from Lean and Obese Zucker and Zucker Diabetic Fatty rats. Drugs in Development. Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 85–93.
Vasselli J.R., deCarr L.B., Velazquez N.: Effects of Alfa-Glucosidase Inhibition on Lipid and Lipoprotein Metabolism in Normal and Insulin-Deficient Diabetic Rats. Drugs in Development Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 125–131.
Abdollahi A., Tulp O.L., Schnitzer-Polokoff R.: The effects of Acarbose on Cholesterogenesis in Obese and obese-Diabetic Rats. Drugs in Development Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 133–143.
Hotta N., Kaluta H., Sano T., Matsumae H., Yamada H. et al.: Long term effect of acarbose on glycaemic control in non-insulin dependent diabetes mellitus: a placebo controlled double blind study. Diab. Med., 10, 134–138, 1993.
Hoffmann J.: Acarbose and glibenclamid in type II-diabetes. A comparative study on efficacy and side effects. In German, Münchener Medizinishe Wochenschrift, 132, 487–490, 1990.
Bayraktar F., Yilmaz C., Ozgen A.G., Kabalak T., Tüzün M., Hamulu F.: Initial results of acarbose treatment in diabetes mellitus. Ulusal Endokrinoloji Dergisi, 4, 47–59, 1994.
deLivia A., Pinon P., Tebar J., Escobar-Jimenez F., deLivia A., de la Calle H., et al.: Efficacia clinica y tolerancia de la acarbose en el tratamiento de pacientes diabeticos no depentientes de la insulina (tipo II). Med. Clin. (Barcelona), 100, 368–371, 1993.
Goto Y., Nakagawa S., Goto Y., Hosoya Y., Orishige H. et al.: Clinical utility of BAY g 5421 (acarbose) on NIDDM. Multicentre double-blind comparative study. Igaku no Ayumi, 149, 591–618, 1989.
Rodier M., Richard J.L., Monnier L., Mirouze J.: Effect of long term acarbose (Bay 5421) therapy on metabolic control of non-insulin dependent diabetes (type II) mellitus. Diab. Metab. 14, 12–14, 1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bayraktar, F., Hamulu, F., Özgen, A.G. et al. Acarbose treatment in obesity: a controlled study. Eat Weight Disord 3, 46–49 (1998). https://doi.org/10.1007/BF03339987
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03339987